Study at a glance
Could vitamin D help with symptoms after COVID-19?
The researchers asked whether vitamin D could help adults with fatigue, meaning tiredness, or other symptoms after COVID-19. In this trial, 80 adults were assigned by chance to vitamin D or an inactive treatment called a placebo for eight weeks. Neither the participants nor the researchers knew who was receiving which treatment during the trial.
Which symptoms improved with vitamin D in this trial?
Compared with placebo, the vitamin D group had better fatigue scores, fewer anxiety symptoms and better results on one test of thinking and memory. The trial did not find clear differences between groups in sleep quality, depression symptoms, some other thinking tests, or the blood markers of inflammation it measured.
Do these results apply to everyone with symptoms after COVID-19?
The results differed across the symptoms and tests measured. An improvement on one thinking test did not mean that every thinking measure improved. These findings come from 80 adults followed for eight weeks. They do not establish the same effects for everyone with ongoing symptoms after COVID-19.
How much vitamin D did this trial use?
The study used 60,000 international units (IU) of vitamin D each week. This describes the trial’s treatment and is not an instruction about how much an individual should take.
Read the full article below ↓Study overview
Charoenporn V et al. (2024) tested whether high-dose vitamin D could improve fatigue and neuropsychiatric symptoms in people with post-COVID syndrome. This was an 8-week, double-blind, randomized, placebo-controlled trial published in Psychiatry and Clinical Neurosciences.
What this study shows
In 80 patients with post-COVID fatigue or neuropsychiatric symptoms, weekly vitamin D (60,000 IU) for 8 weeks improved fatigue scores (CFQ-11), reduced anxiety symptoms (DASS-21 anxiety), and improved cognitive test performance (ACE) compared with placebo. Sleep quality (PSQI), depression symptoms (DASS-21 depression), inflammatory markers (IL-6, CRP), and some cognitive measures (TMT) did not show significant between-group differences.
Key details
- Design: double-blind randomized placebo-controlled trial
- Participants: 80 adults with post-COVID fatigue or neuropsychiatric symptoms
- Intervention: vitamin D3 60,000 IU weekly for 8 weeks vs placebo
- Outcomes measured: fatigue (CFQ-11), mood (DASS-21), sleep quality (PSQI), cognition (ACE, TMT), IL-6, CRP
- Main finding direction: fatigue improved; anxiety improved; cognition improved; several secondary outcomes showed no clear change vs placebo
Related study page
For sleep-related trial evidence in this library, see: vitamin-d-sleep-quality-trial
Primary source
Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed)
Related reading
A Comprehensive Scoping Review on Diet and Nutrition in Relation to Long COVID-19 Symptoms and Recovery
Eligible studies examined dietary intake, nutritional status, or nutrition-related interventions in adults with long COVID-19.
Original paper ↗Read more →Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers
The objective of current study is to analyze the vitamin D level in COVID-19 patients and its impact on the disease severity.
Original paper ↗Read more →Association between Average Vitamin D Levels and COVID-19 Mortality in 19 European Countries: A Population-Based Study
This study aimed to update the initial report studying the link between vitamin D deficiency and COVID-19 mortality by using multi-country data in 19 European countries up to the middle of June 2023.
Original paper ↗Read more →Association of Vitamin D Supplementation with Glutathione Peroxidase (GPx) Activity, Interleukine-6 (IL-6) Levels, and Anxiety and Depression Scores in Patients with Post-COVID-19 Condition
We conducted a self-controlled study in which 54 participants with PCC were supplemented with vitamin D3 (n = 28 bolus and n = 26 daily) for 2 months.
Original paper ↗Read more →Coronavirus Disease 2019 (COVID-19): A Literature Review from a Nursing Perspective
As the COVID-19 pandemic ravages the world, nursing resources, and capacities play an essential role in disease management.
Original paper ↗Read more →Correlation between 25-hydroxyvitamin D/D3 Deficiency and COVID-19 Disease Severity in Adults from Northern Colorado
Participants consented to enrollment for a period of 6 months and provided biospecimens at multiple visits for longitudinal analysis.
Original paper ↗Read more →COVID-19: Role of Nutrition and Supplementation
Unfortunately, to date, no specific treatments have been found for the cure of this virus and, therefore, it is advisable to implement all possible strategies in order to prevent infection.
Original paper ↗Read more →Dramatic Deterioration of Subclinical Hyperparathyroidism in Children and Adolescents During the Post-COVID-19 Period
Vitamin D is a steroid hormone, essential for the immune system and bone health.
Original paper ↗Read more →Effect of a Single High-Dose Vitamin D3 on the Length of Hospital Stay of Severely 25-Hydroxyvitamin D-Deficient Patients with COVID-19
In this ancillary analysis of a multicenter, double-blinded, randomized, placebo-controlled trial, we investigated the effect of a single high dose of vitamin D3 on the length of hospital stay of patients with severe 25-hydroxyvitamin D deficiency and COVID-19.
Original paper ↗Read more →Effect of Single High Dose Vitamin D Substitution in Hospitalized COVID-19 Patients with Vitamin D Deficiency on Length of Hospital Stay
Vitamin D and its role in the coronavirus-19 disease (COVID-19) pandemic has been controversially discussed, with inconclusive evidence about vitamin D3 (cholecalciferol) supplementation in COVID-19 patients.
Original paper ↗Read more →Efficiency of the Vitamin D Status Diagnosticator amongst Geriatric Patients with COVID-19
This study aimed to evaluate the VDSD’s effectiveness in pinpointing hypovitaminosis D in older adults affected by COVID-19.
Original paper ↗Read more →Evaluation the level of vitamin D and its relationship with clinical symptoms in patients with COVID-19 referred to the medical center in Bam city
A checklist consisting of demographic variables was used to gather data, and laboratory assessments of serum 25(OH) D were evaluated and documented.
Original paper ↗Read more →Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial
Background and Objectives: Vitamin D supplementation plays a key effect in lowering cytokine storms among COVID-19 patients by influencing the activity of the renin-angiotensin system and the production of the angiotensin-2 converting enzyme.
Original paper ↗Read more →High Prevalence of Hypocalcemia in Non-severe COVID-19 Patients: A Retrospective Case-Control Study
The biochemical parameters were compared with age, sex, and 25-hydroxyvitamin D matched healthy adult controls (1:1 ratio) derived from the Chandigarh Urban Bone Epidemiological Study (CUBES).
Original paper ↗Read more →Immune Signatures in Post-Acute Sequelae of COVID-19 (PASC) and Myalgia/Chronic Fatigue Syndrome (ME/CFS): Insights from the Fecal Microbiome and Serum Cytokine Profiles
While there are many postulates for the etiology of post-viral chronic fatigue and other symptomatology, little is known.
Original paper ↗Read more →Inflammation, underweight, malignancy and a marked catabolic state as predictors for worse outcomes in COVID-19 patients with moderate-to-severe disease admitted to Internal Medicine Unit
Patients who died were older, more frequently underweight, affected by malignant neoplasms and on statin therapy compared to patients eventually discharged.
Original paper ↗Read more →Long-term clinical and biochemical residue after COVID-19 recovery
The long-term health consequences of coronavirus disease 2019 (COVID-19) are still unclear.
Original paper ↗Read more →Metabolic Healthy Obesity, Vitamin D Status, and Risk of COVID-19
We studied 353,299 UK Biobank participants from England with a mean age of 67.7 years.
Original paper ↗Read more →Retrospective Clinical Investigation into the Association Between Abnormal Blood Clotting, Oral Anticoagulant Therapy, and Medium-Term Mortality in a Cohort of COVID-19 Patients
People affected by COVID-19 are exposed to abnormal clotting and endothelial dysfunction, which may trigger thromboembolic events.
Original paper ↗Read more →Vitamin D Levels in the Pre: and Post-COVID-19 Pandemic Periods and Related Confinement at Pediatric Age
Coronavirus disease 2019 (COVID-19) restrictions have been correlated with vitamin D deficiency in children, but some uncertainties remain.
Original paper ↗Read more →Vitamin D status in children with COVID-19: does it affect the development of long COVID and its symptoms?
This study aimed to determine vitamin D status in children with COVID-19 and assess its impact on the clinical course of disease and long COVID development.
Original paper ↗Read more →Original sources
Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed)
Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed).
Publication details
Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial (PubMed)